External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

IMS 2026

We will be contributing to topics related to
-
12:00 PM
Duration 240mins Glasgow, Scotland
CEVOLUTION: A randomized phase III trial comparing cevostamab plus pomalidomide and dexamethasone (pom-dex) versus standard of care (SOC) in relapsed/refractory multiple myeloma (RRMM)
Rakesh Popat, Adam Cohen, Amrita Krishnan, Divya Samineni, Elena Zamagni, Hira S. Mian, Joshua Richter, Kerstin Trunzer, Tulika Tyagi, Leanne Richardson, Paresh Sewpaul,, Sammy Chebon, Tina Nielsen, Binod Dhakal
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:30 PM
Duration 12mins Glasgow, Scotland
A fixed-duration, modified cevostamab dosing regimen induces durable remissions that continue after completion in BCMA-naïve pts with relapsed/refractory multiple myeloma (RRMM): CAMMA 1 Arm A results
Ameet Mishra, Amrita Krishnan, Divya Samineni, Henning Schade, Leanne Richardson, Ravi Vij, Sammy Chebon, Simon Harrison, Suzanne Trudel, Tulika Tyagi, Vanessa Grassi
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 12mins Glasgow, Scotland
Cevostamab plus pomalidomide (pom) and dexamethasone (dex) induces durable remissions in BCMA-naïve patients with relapsed/refractory multiple myeloma (RRMM): CAMMA 1 Arm B extended follow-up data
Andrew Spencer, Hira S Mian, Kihyun Kim, Laura Paris, Rakesh Popat, Simon J Harrison, Anna Caroline Hasselbalch, Noa Lavi, Tomas Jelinek, Monika Szarejko, Sebastian Grosicki, Irwindeep Sandhu, Vanessa Grassi, Tulika Tyagi, Paresh Sewpaul, Leanne Richardson, Ameet Mishra, Suzanne Trudel
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon